Car T Kymriah denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Kymriah as Experimental

UnitedHealthcare may classify Kymriah (tisagenlecleucel) as "experimental or investigational" when the specific use being requested — the particular diagnosis subtype, age group, or line-of-therapy setting — falls outside or at the edge of the FDA-approved labeling, or when UHC's internal coverage policy has not yet been updated to reflect a newer labeled indication. Given the life-threatening cancers for which Kymriah is approved, this denial type must be addressed urgently and is among the most commonly reversed in external review for oncology CAR-T therapies.

## Why It Is Appealable

Kymriah holds FDA approval for specific hematologic malignancies within defined patient populations. For any use that is consistent with the FDA-approved label, UHC cannot lawfully sustain an experimental denial. Federal and state law provide strong protections:

• ACA §2719 / ERISA §503: Full internal appeal plus independent external review by an oncology-specialized IRO.
• External review window: Generally four months from the final internal denial — but given clinical urgency, pursue expedited options immediately.
• Expedited external review: For life-threatening conditions, decisions are typically required within 72 hours. This pathway is strongly recommended given the nature of the underlying diagnosis.
• State external review laws: Many states have enacted additional protections for experimental-use denials of life-threatening conditions, providing an additional layer of appeal rights beyond federal minimums.

## Appeal Process and Timeline

1. Obtain the denial in writing with the specific policy language UHC is applying to classify this use as experimental. 2. Pull the current FDA prescribing information for Kymriah from FDA.gov or DailyMed, confirming the approved indication and patient population. 3. Confirm the prescribed use is on-label: If yes, the experimental designation is facially unsupportable and should be reversed at the internal appeal stage. 4. If the use is off-label but supported by evidence: Gather the strongest available published evidence (peer-reviewed literature, applicable NCCN guideline category, major professional society recommendation) — your oncologist should curate this. 5. File an expedited internal appeal and, simultaneously or immediately after, file for expedited external review.

## Documentation to Gather

• FDA approval documentation: Current prescribing information for Kymriah confirming the labeled indication and patient eligibility criteria.
• Diagnosis and eligibility confirmation: Pathology, cytogenetics, flow cytometry, bone marrow biopsy, and full prior-treatment history confirming the patient meets the labeled criteria — obtain the exact eligibility requirements from the FDA label itself, not from third-party summaries.
• Prior treatment history with outcomes: A complete dated list of prior lines of therapy, responses, and the basis for the relapsed/refractory determination, mapped against the label's prior-therapy requirements.
• Treating oncologist letter: A detailed letter confirming on-label use, citing the FDA indication, and referencing the applicable NCCN guideline organization category for this use.
• Clinical urgency documentation: Chart notes documenting disease trajectory, performance status, and the clinical risk of delay — essential for both expedited review and substantive merit.

## Criteria-Mapping Structure

Obtain Kymriah's FDA prescribing information and UHC's current coverage policy for tisagenlecleucel. For each criterion in the coverage policy (prior lines of therapy, diagnosis subtype, performance status, organ function requirements), document the exact chart finding that satisfies it — with date, source, and value as recorded in the medical record. This structured mapping is the most effective format for CAR-T appeals and gives the IRO's oncology reviewer everything needed to reverse the denial.